Who is sponsoring NCT03426540?

NCT03426540 is sponsored by Tianjin Medical University Eye Hospital.

What drugs are being tested in NCT03426540?

Interventions in NCT03426540: Conbercept.

What condition does NCT03426540 study?

NCT03426540 studies Early Proliferative Diabetic Retinopathy.

Is NCT03426540 still recruiting?

NCT03426540 is currently completed. Last updated 30 April 2019.

Last reviewed 2019-04-30 · How we verify

NCT03426540

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravitreal Conbercept After Vitrectomy

Completed EARLY_PHASE1 Last updated 30 April 2019

What this trial tests

EARLY_PHASE1 trial testing Conbercept in Early Proliferative Diabetic Retinopathy in 50 participants. Completed in 28 February 2019.

Timeline

1 January 2017

Primary endpoint
30 March 2018

28 February 2019

Quick facts

Lead sponsor	Tianjin Medical University Eye Hospital
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	50
Start date	1 January 2017
Primary completion	30 March 2018
Estimated completion	28 February 2019

Drugs / interventions tested

Conbercept — full drug profile →

Conditions studied

Early Proliferative Diabetic Retinopathy — all drugs for Early Proliferative Diabetic Retinopathy →

Sponsor

Tianjin Medical University Eye Hospital

Who can join

Adults 28 to 80, any sex, with Early Proliferative Diabetic Retinopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and efficacy of intravitreal conbercept after vitrectomy for the management of early-stage proliferative diabetic retinopathy (PDR). Hypothesis: intravitreal conbercept therapy may promote functional and anatomic recovery from PDR. intravitreal conbercept therapy may be a useful and safe method for improving visual outcomes of surgery for early-stage PDR.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy.
Arrigo A, Aragona E, Bandello F. · · 2022 · cited 115× · PMID 35451900 · DOI 10.1080/07853890.2022.2064541
Safety and efficacy of intravitreal conbercept injection after vitrectomy for the treatment of proliferative diabetic retinopathy.
Ren X, Bu S, Zhang X, Jiang Y, et al · · 2019 · cited 26× · PMID 30872770 · DOI 10.1038/s41433-019-0396-0
Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy.
Dervenis P, Dervenis N, Smith JM, Steel DH. · · 2023 · cited 13× · PMID 37260074 · DOI 10.1002/14651858.cd008214.pub4

Verify or expand the search:

Other trials of Conbercept

Trials testing the same drug.

NCT06717412 — Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy · NA · recruiting
NCT06305143 — Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy · Phase 4 · active not recruiting
NCT05222633 — Anti-VEGF in Real-world · unknown
NCT04782115 — Evaluation of RC28-E Injection in Diabetic Macular Edema · Phase 2 · completed
NCT04627402 — Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE) · NA · unknown

Other Tianjin Medical University Eye Hospital trials

Trials by the same sponsor.

NCT07494799 — Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear · not yet recruiting
NCT07449247 — PROTECT-Study: Prospective Research on Optimizing Atropine Concentration Escalation for Children's Myopia Prevention · Phase 1, PHASE2 · not yet recruiting
NCT05728476 — Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Dia · NA · recruiting
NCT05990829 — Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed · Phase 4 · unknown
NCT07106268 — Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03426540 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Eye Hospital
Last refreshed: 30 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03426540.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing